LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

Dexcom is in seventh heaven: A year after its initial FDA submission, the diabetes tech maker has finally gotten the green light to begin rolling out its latest continuous glucose monitor system in ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...

DexCom, Inc. DXCM announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has ...

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...

For quite some time now, there has been significant hype around the Dexcom G7, which received a CE mark in March. This week, as part of a global streaming launch event, Dexcom revealed how the product ...

Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...